BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
PLYMOUTH, Minn., Nov. 16, 2016 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the Company plans to participate in the 28th Annual Piper Jaffray Healthcare Conference in New York, NY.
Entellus Medical’s management is scheduled to present Tuesday, November 29, 2016 at 2:00pm ET. Interested parties can access a live webcast on the investor relations section of the Company’s website at: www.entellusmedical.com.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. The Entellus Medical platform of products provide effective and easy-to-use solutions to simplify everything from diagnosis and patient selection, to complex case revisions and post-operative care. Entellus Medical’s three core product lines, XprESS™ Multi-Sinus Dilation Systems, MiniFESS™ Surgical Instruments, and FocESS™ Imaging & Navigation, combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the office and simplify OR based treatment. Entellus Medical is committed to broadening its product portfolios with high-quality and purposeful innovations for the global ENT market. For more information, please visit the Company's website at www.entellusmedical.com.
Contact: Lynn Pieper Lewis 415-937-5402 [email protected]
